Evidence map›Paper›PMID 32530723›Full record

ArticleHuman vaccines & immunotherapeutics2020

Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein.

Heather L Torrey, Valarmathy Kaliaperumal, Yogesh Bramhecha, Genevieve M Weir, Ann R Falsey, Edward E Walsh, Joanne M Langley, Bert Schepens, Xavier Saelens, Marianne M Stanford

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. The Current Status of COVID-19 Vaccines.Frontiers in genome editing · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Heather L TorreyIMV Inc ., Dartmouth, NS, Canada.ORCID 0000-0003-4278-6411
Valarmathy KaliaperumalIMV Inc ., Dartmouth, NS, Canada.
Yogesh BramhechaIMV Inc ., Dartmouth, NS, Canada.ORCID 0000-0002-6888-7301
Genevieve M WeirIMV Inc ., Dartmouth, NS, Canada.ORCID 0000-0002-6285-7187
Ann R FalseyUniversity of Rochester , Rochester, NY, USA.
Edward E WalshUniversity of Rochester , Rochester, NY, USA.ORCID 0000-0002-8792-8877
Joanne M LangleyCanadian Center for Vaccinology (IWK Health Centre and Nova Scotia Health Authority and Dalhousie University) , Halifax, NS, Canada.ORCID 0000-0003-3270-7345
Bert SchepensVIB-UGent Center for Medical Biotechnology , Ghent, Belgium.ORCID 0000-0002-2028-1984
Xavier SaelensVIB-UGent Center for Medical Biotechnology , Ghent, Belgium.ORCID 0000-0003-0686-0311
Marianne M StanfordIMV Inc ., Dartmouth, NS, Canada.ORCID 0000-0003-0432-3707
Dalhousie University · CAGhent University Hospital · BEUniversity of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The small hydrophobic (SH) glycoprotein of human respiratory syncytial virus (RSV) is a transmembrane protein that is poorly accessible by antibodies on the virion but has an ectodomain (SHe) that is accessible and expressed on infected cells. The SHe from RSV strain A has been formulated in DPX, a unique delivery platform containing an adjuvant, and is being evaluated as an RSV vaccine candidate. The proposed mechanism of protection is the immune-mediated clearance of infected cells rather than neutralization of the virion. Our phase I clinical trial data clearly showed that vaccination resulted in robust antibody responses, but it was unclear if these immune responses have any correlation to immune responses to natural infection with RSV. Therefore, we embarked on this study to examine these immune responses in older adults with confirmed RSV infection. We compared vaccine-induced (DPX-RSV(A)) immune responses from participants in a Phase 1 clinical trial to paired acute and convalescent titers from older adults with symptomatic laboratory-confirmed RSV infection. Serum samples were tested for anti-SHe IgG titers and the isotypes determined. T cell responses were evaluated by IFN-γ ELISPOT. Anti-SHe titers were detected in 8 of 42 (19%) in the acute phase and 16 of 42 (38%) of convalescent serum samples. IgG1, IgG3, and IgA were the prevalent isotypes generated by both vaccination and infection. Antigen-specific T cell responses were detected in 9 of 16 (56%) of vaccinated participants. Depletion of CD4

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAgedAnimalsAntibodies, ViralFemaleHumansMiceMice, Inbred BALB CT-LymphocytesAntibodies, ViralRespiratory Syncytial Virus VaccinesadultagedantibodyB cellimmunizationimmunotherapynatural infectionRespiratory syncytial virusT cellvaccine

Identifiers

PMID32530723
PMCPMC7553696
OpenAlexW3035761049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.